Skip to main content
Figure 2 | BMC Psychiatry

Figure 2

From: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

Figure 2

Regression scatterplots of mean change in prolactin at endpoint (LOCF) by dose and gender. Figure 2 shows the scatterplots, regression lines, and resulting equations for the relationship between endpoint prolactin change and dose, by gender. In the equation, "dose" refers to the calculated oral equivalent daily dose (10.7, 14.5, or 21.4 mg/day), not the actual injected dose. Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg/2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg/4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg/2 weeks, approximate oral equivalent 20 mg/day (N = 141).

Back to article page